Evotec SE

EVT

DE0005664809

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 09:49:42 2024-05-06 am EDT			5-day change	1st Jan Change
9.628 ^EUR	-1.35%		+0.47%	-54.56%

02:03pm	EVOTEC : Warburg Research reiterates its Buy rating	ZD
May. 03	EVOTEC : RBC reiterates its Buy rating	ZD

EVOTEC : Morgan Stanley sets new Sell rating

August 10, 2022 at 04:44 am EDT

Morgan Stanley is negative and recommends to sell the stock. The target price is revised downwards from EUR 42 to EUR 32.

Latest news about Evotec SE

EVOTEC : Warburg Research reiterates its Buy rating	08:03am	ZD
EVOTEC : RBC reiterates its Buy rating	May. 03	ZD
Bayer: strategic collaboration with Evotec	Apr. 30	CF
Evotec, Bayer to Collaborate on New Cardiovascular Disease Therapies	Apr. 30	MT
Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases	Apr. 30	MT
Bayer and Evotec Collaborate to Advance Precision Cardiology	Apr. 30	CI
EVOTEC : Deutsche Bank gives a Buy rating	Apr. 26	ZD
The specter of stagflation rears its ugly head again	Apr. 25
EVOTEC : Buy rating from Deutsche Bank	Apr. 25	ZD
Top Midday Decliners	Apr. 24	MT
Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15	Apr. 24	DP
Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	Apr. 24	MT
Transcript : Evotec SE, 2023 Earnings Call, Apr 24, 2024	Apr. 24
Technology Stocks Gain Amid Tesla's EV Plans as US Equity Futures Turn Mostly Higher Pre-Bell	Apr. 24	MT
Sector Update: Health Care	Apr. 24	MT
Top Premarket Decliners	Apr. 24	MT
RBC upgrades Evotec to 'Outperform' after figures and outlook	Apr. 24	DP
EVOTEC : Warburg Research reaffirms its Buy rating	Apr. 24	ZD
Jefferies rates Evotec a 'Buy' after figures and outlook	Apr. 24	DP
EVOTEC : Jefferies reaffirms its Buy rating	Apr. 24	ZD
EVOTEC : RBC keeps its Buy rating	Apr. 24	ZD
Evotec crashes - Too much uncertainty	Apr. 24	DP
Evotec SE Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
U.S. Futures, European Stocks Mixed	Apr. 24	DJ
Evotec under pressure - outlook disappointed	Apr. 24	DP

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - BofA Securities Health Care Conference

Related indices

STOXX EUROPE 600 (EUR) , MDAX

More about the company

Income Statement Evolution

More financial data

Ratings for Evotec SE

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.76 EUR

Average target price

22.69 EUR

Spread / Average Target

+132.48%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVOTEC SE	-54.56%	1.86B
MODERNA, INC.	+24.48%	47.9B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-2.52%	40.7B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+8.97%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.68%	19.27B
BIO-TECHNE CORPORATION	-0.08%	12.15B
MEDPACE HOLDINGS, INC.	+28.37%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.34%	11.99B

Other Biotechnology & Medical Research

Evotec SE

Equities

EVT

DE0005664809

Biotechnology & Medical Research

EVOTEC : Morgan Stanley sets new Sell rating

Latest news about Evotec SE

Chart Evotec SE

Company Profile

Income Statement Evolution

Ratings for Evotec SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research